Merkel Cell Carcinoma is a rare and aggressive form of skin cancer that originates from neuroendocrine cells located within the skin. This malignancy is known for its rapid growth and high potential for early metastasis to lymph nodes and distant organs. Because of its aggressive nature, ongoing investigations into disease biology and treatment innovations are frequently presented at global scientific forums such as a Cancer Conference, where researchers discuss emerging diagnostic approaches and therapies targeting neuroendocrine skin cancer.

Merkel cell carcinoma develops when genetic damage disrupts the normal growth of Merkel cells, which are specialized cells involved in sensory perception within the skin. In many cases, the development of this cancer is associated with the Merkel cell polyomavirus, a virus that integrates into the DNA of skin cells and promotes uncontrolled cell division. In other cases, ultraviolet radiation from sun exposure contributes to genetic mutations that drive malignant transformation. The disease most commonly affects older adults and individuals with weakened immune systems, highlighting the important role of immune surveillance in controlling abnormal cell growth.

Clinically, Merkel cell carcinoma often appears as a painless, firm, rapidly growing nodule on sun-exposed areas of the skin such as the face, neck, or arms. Because the tumor can grow quickly and spread early, prompt diagnosis is essential. Physicians typically evaluate suspicious lesions through biopsy and histopathological examination to confirm the presence of malignant cells. Imaging studies and sentinel lymph node biopsy may also be performed to determine whether the cancer has spread beyond the primary tumor site.

Treatment of Merkel cell carcinoma often involves a multidisciplinary approach that includes surgery, radiation therapy, and systemic treatments. Surgical removal of the primary tumor with clear margins is usually the first step in management. Radiation therapy may be used after surgery to reduce the risk of local recurrence. In recent years, immunotherapy has become an important treatment option for advanced disease, as immune checkpoint inhibitors can stimulate the immune system to recognize and attack cancer cells. Continued research aims to improve early detection, identify predictive biomarkers, and develop more effective therapies for patients diagnosed with Merkel cell carcinoma.